CompletedPhase 2NCT03483961

Trial of a Chikungunya Vaccine, PXVX0317 CHIKV-VLP, in Healthy Adults

Studying Chikungunya

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Bavarian Nordic
Principal Investigator
James McCarty, MD
Emergent BioSolutions
Intervention
CHIKV VLP/unadjuvanted(biological)
Enrollment
445 enrolled
Eligibility
18-45 years · All sexes
Timeline
2018 – 2020

Study locations (3)

Collaborators

Emergent BioSolutions

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03483961 on ClinicalTrials.gov

Other trials for Chikungunya

Additional recruiting or active studies for the same condition.

See all trials for Chikungunya →

← Back to all trials